Introduction
Stroke is one of the leading causes of death worldwide and can also be a source of permanent disability survivors. Cerebral ischemic stroke accounts for approximately 80% of all strokes (Chen et al., 2012；Donnan et al., 2008；Feigin et al., 2003 . The most common cause of ischemic stroke is the occlusion of a blood vessel by a thrombus, resulting in an immediate loss of the normal supply of oxygen and glucose to cerebral tissue (Genoverse et al., 2011) . A variety of therapeutic strategies are currently being considered as a means of minimizing the neuronal damage resulting from ischemia, leading to increasing study of the pathological mechanisms underlying stroke.
The diterpenoid tanshinone IIA (TSA) is an important component of Chinese medicine, made from the dried rhizome of danshen, Salvia miltiorrhiza. This herb is traditionally used for the treatment of cardiovascular and cerebrovascular diseases, including ischemic stroke (Yang et al., 2008; Xu et al., 2009) . TSA is a derivative of phenanthrenequinone; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[8,7-g] [1]benzoxole-10, 11-dione ( Fig. 1 ). Many plant-derived terpenoids have been found to possess anti-inflammatory and anti-neoplastic properties, and TSA has been reported to modulate many kinds of biological activities, including the quenching of reactive oxygen species, and antagonism of calcium-promoted events. Such molecular changes may account for the ability of TSA to promote microcirculatory function, inhibit neutrophil migration, and exert anti-tumor effects (Han et al., 2008) . TSA is able to traverse the blood brain barrier although the brain content is limited to 30% of 5 the plasma concentration (Chen et al., 2007) , and this could relate to its effects in reducing the volume of cerebral infarction and maintenance of neuronal function (Lam et al., 2003) . TSA has been shown to have protective effects against focal cerebral ischemia/reperfusion (I/R) injury in animal models (Tang et al., 2010; and has been proposed as a potential therapeutic agent in heart disease, liver disease and cancer treatment (Dai et al., 2012 ).
The present study was intended to evaluate the potentially protective effects of TSA in a stroke model and illuminate on the mechanisms that could underlie this. A suture-occlusion method was used to block the middle cerebral artery, followed by release of the block thus initiating reperfusion. Levels of the pro-inflammatory indicators glial fibrillary acidic protein (GFAP) were increased after I/R together with levels of two caspases associated with apoptosis; caspase-3 and capsase-8.
Treatment with TSA after the surgical procedure partially reversed all of the changes caused by I/R. This provides a mechanistic basis accounting for the utility of TSA on the treatment of stroke. 
Experimental procedures

The Middle Cerebral Artery Occlusion Model
Focal cerebral ischemia was induced by transient middle cerebral artery occlusion in the right hemisphere (Genoverse et al., 2011) . Rats were anesthetized with 10% chloral hydrate (350ml/kg, administered i.p. in 0.3 ml saline). The surgery to occlude the medial carotid artery consisted of the insertion of a 4-0 nylon filament (Beijing Shadong Biology Company, Beijing, China; diameter 0.26mm) precoated with a hardener with diameter 0.34 mm, via the external carotid artery into the internal carotid artery to block the inflow of blood into the medial carotid artery according to the procedure originally described by (Longa et al., 1989) and modified by (Melani et al., 1999) . After 2 hours of ischemia, the nylon filament was carefully pulled out to establish reperfusion. Sham-operated (control) rats underwent the same surgical procedures without occlusion of the common carotid arteries. Rectal temperature was recorded and maintained at 37°C throughout the whole surgical procedure. The operation of was carried out with all efforts to minimize animal suffering.
This transient medial carotid artery occlusion caused measurable neurological deficits. We used Longa and Bederson's 5-point scale within 24 h after recovery from 7 anesthetic to judge whether the surgery was successful. The scoring system was as follows: 0, no deficit; 1, flexion of the contralateral torso and forelimb when held by tail; 2, circling to affected side; 3, leaning to affected side; 4, no spontaneous locomotor activity or barrel rolling. Any animal without deficit in the intra-ischemic period was excluded from the study .
Study design in animal models
Sixty-four rats were randomized into eight groups (n=8 for each group): Sham (control) animals were subjected to surgical procedures without artery occlusion shock and treated with a daily i.p. injection of physiological saline for 7 or15 days..
I/R operated rats were subjected to artery occlusion for 2 hours followed by reperfusion. They then received daily i.p. injections of saline for 7 or 15d respectively.
I/R operated rats subsequently treated with a low dose (4 mg/kg/day i.p.) or a high dose of TSA (8mg/kg/day).
Brain sample preparations
After the experiments were completed, rats were deeply anesthetized with 10% chloral hydrate (350 ml/kg), and the heart was exposed to perfuse transcardially with cold 0.1M phosphate-buffered saline PH 7.4 through the left ventricle. After dissection one half of the brain was immediately frozen in -80 °C refrigerator (for Western blotting) and the other half fixed in 4% paraformaldehyde overnight (for immunohistochemistry and hematoxylin-eosin staining). Thereafter, fixed tissue was transferred into PBS/0.02% Na azide at 4°C until use. Afterward, the fixed brain tissues were further processed by dehydration in graded ethanol prior to paraffin 8 embedding. Finally, the blocks were coronally cut in serial 5-µm-thick sections and stored at 4 °C before being stained.
Hematoxylin-eosin Staining and Immunohistochemistry
After deparaffinization, sections were washed in double distilled water for ten m, and were incubated in hematoxylin, then treated with with 0.2% hydrochloric acid.
Subsequently, eosin red was used in a 2 m incubation, and this was followed by fixation in 95% alcohol.
Immunohistochemistry was performed on paraffin embedded sections. After Harbor, ME, USA) for 1 h at room temperature. To ascertain that blots were loaded with equal amounts of protein lysates, they were incubated in the presence of the antibody against β-actin 1:1000 (Santa Cruz Biotechnology). Chemiluminescence was detected with ECL Plus substrate kit (Beyotime, China) by Image Quant 350 (GE Healthcare, Little Chalfont, UK).
Image and Statistical Analysis
Immunostaining was quantified using a Nikon Eclipse 80i microscope (Nikon, Japan) and images acquired with a Nikon DS high-resolution digital color camera (1280 × 1024 pixel) using NIS-Elements AR 3.0 software. Digital images were analyzed using Ver.3.00 analysis program (Nikon). The percentage of immunostained area (field area of immunostaining/total image area ×100) was determined for all the markers studied by averaging several images per section that cover all or most of the region of study. Western blots bands were analyzed by Image J software. All experiments were repeated at least twice, with n=6-8 animals per group per marker.
All quantitative comparisons were performed on sections processed at the same time.
Single ANOVA statistical analysis was used to assess the significance of the differences in anti-GFAP, anti-caspase-3, anti-caspase-8, among the animal groups. A two-tailed P-value of less than 0.05 was considered significant. All the statistical analysis was carried out without knowledge of the treatments (Impellizzeri et al., 2011) .
Results
The consequence of ischemic injury on a variety of relevant parameters was studied together with the outcome of daily treatment with TSA following surgery for 7 or 15 days. It was found that all values obtained after TSA treatment following sham surgery, did not differ significantly from the corresponding values following sham 11 surgery alone. Thus, in order to simplify the figures these results are not shown.
Hematoxylin-eosin staining
The cerebral infarction cause by I/R was examined in brain slices stained with hematoxylin-eosin (Fig. 2) . Sections from the control group had normally staining brain tissue ( Fig. 2A,E) , whereas the I/R treatment groups had a paler less stained region reflecting the area of ischemic damage in the infarcted area (Fig. 2B,F) .
Treatment with TSA resulted in an incomplete reversal of the loss of staining in the infarcted area. The infarct volume (white area) was attenuated in these groups.
This was marginal in the group receiving the lower dose of TSA for 7d (Fig. 2C) , and especially pronounced in the group receiving the higher dose of TSA for 15d (Fig. 2H) suggesting a dose-and time-response restorative relationship.
Levels of GFAP in the cortex
Immunohistochemical staining for GFAP revealed that I/R treatment led to a significant and sustained increase in the GFAP levels in the injured cortex relative to controls (Fig. 3A) . GFAP and CD11b levels were quantitatively confirmed by densitometric analysis (Fig. 3B) 
Discussion
Middle cerebral artery occlusion is a generally accepted model of cerebral ischemia (Hoffman et al., 2006) . The findings presented suggest that indices of apoptosis in rat brain induced by I/R can be considerably reduced (but not totally prevented) by TSA.
The reduction of GFAP content after TSA treatment, further indicated that TSA can mitigate the inflammation and the impairments in metabolism induced by I/R.
Astrocytes, the most abundant population of glial cells that constitute the microenvironment of the central nervous system (Liu et al., 2012) , are intimately associated with the brain homeostasis and maintenance of brain function. While astrocytes are significant in effects repair processes in the CNS, excessive prolongation of their activation is known to lead to undesirable inflammatory outcomes (Sun et al., 2012) . Since GFAP is a marker of astrocytic reactivity our 13 findings suggest that TSA may owe some of its neuroprotective effects in ischemia regions by restoring the resting condition of astrocytes.
A substantial body of evidence suggests that apoptosis after cerebral I/R injury is a major pathway leading to cell death (Faruk et al., 2010) . After transient occlusion of the middle cerebral artery followed by reperfusion, the number of apoptotic cells in the striatum and cortex of rats was directly proportional to the duration of ischemia (Raff et al., 1993) . The mechanism of apoptosis involves a signal transduction process by which intracellular protein is degraded by a family of cysteine-dependent aspartate-directed proteases (caspases). The caspases, central regulators of apoptosis, have been demonstrated to play a key role in ischemia-induced cytotoxicity in vivo and in vitro (Bi et al., 2008; Lee et al., 2007; Shimmyo et al., 2008) . Based on their function, caspases are classified into two groups, initiator caspases such as caspase-8, and effector caspases such as caspase-3. Generally, the initiator caspases activate downstream effector caspases by a proteolytic cascade, resulting in the cleavage of a variety of cellular substrates involved in apoptosis (Liu et al. 2011a ). Caspase-3 can be activated by upstream initiator caspases such as caspase-8 through two distinct pathways, i.e., the death receptor-mediated extrinsic caspase-8 pathway or the mitochondria dependent-cytochrome c/caspase-9 intrinsic pathway, respectively (Hu et al., 2003) . Caspase-3 has been shown to be up-regulated and activated in ischemic brain tissue (Rami et al., 2003) , and genetic deletion or pharmacologic inhibition of caspase-3 leads to reduced neuronal death in the ischemic brain (Le et al., 2002) . The protective effect of neuronal deletion of caspase-8 has also been shown 14 following impact injury to the brain. Such deletion led to reductions in lesion size, the extent of neuronal cell death and less activation of caspase-3. Behaviorally impacted animals with deletion of the caspase-8 gene had a lower neuropathological score, better learning performance, superior retention of spatial memory and improved sensorimotor function (Krajewska et al., 2011) . Caspase-3 activity increased when myocardial cells were treated with angiotensin II and TSA greatly inhibited this elevation (Hong et al., 2010) . Apoptosis of cultured myocardial cells has also been reported to be blocked by TSA and this was attributed to inhibition of caspase-3 activity (Jin et al., 2013) . Our finding parallels these reports in that the levels of caspases in brain tissue were significantly increased when rats were subjected to I/R, and that TSA treatment greatly reduced the magnitude of this increase. The results presented here show that TSA inhibited ischemia-induced cell death in the entorhinal cortex. This finding parallels that of a study using prostatic cancer cells, where TSA also had an anti-apoptic effect (Won et al., 2010) . Since many neurodegenerative diseases involve cell death and inappropriately elevated levels of immune activity, it is likely that an agent such as TSA with anti-inflammatory and anti-apoptic properties, will also find application in the treatment of a broader range of age-related diseases of the nervous system. For example, a protective effect of TSA has been reported in animal models of Alzheimer's disease (Yin et al., 2008 , Jiang et al., 2014 .
In animals subjected to I/R and not treated with TSA, the indices of damage were generally lower 15 days after surgery than after 7 days. Thus the effect of TSA may be to improve or accelerate any intrinsic recovery possible after a serious I/R insult.
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Conclusions
The present study found that TSA protects nerve cells from I/R-induced apoptosis.
This neuroprotective effect appears to involve several processes, including suppression of excess activation of glial cells, and inhibiting the activity of caspase-3
and caspase-8. The initial cellular site of TSA action, which can lead to a sequence of protective events, remains to be determined. Furthermore other properties of TSA such as its ability to inhibit platelet aggregation (Liu et al., 2011b) may also contribute to its reputed effectiveness in stroke treatment.
It is noteworthy that, since TSA was effective when administered after the induced lesion, this allows its consideration as a therapeutic drug. TSA seems to be an appropriate candidate for the treatment of stroke or other apoptosis-related brain diseases. Further studies are needed in order to form a strong basis for human clinical trials. days. *: P < 0.05 differs from corresponding control group; #: P < 0.05 also differs from corresponding high-dose TSA-treated group. 
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